Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 3
2009 5
2010 4
2011 5
2012 4
2013 10
2014 6
2015 4
2016 9
2017 4
2018 4
2019 4
2020 5
2021 6
2022 8
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Among authors: chekerov r. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design.
Inci MG, Sehouli J, Schnura E, Lee M, Roll S, Reinhold T, Klews J, Kaufner L, Niggemann P, Groeben H, Toelkes J, Reisshauer A, Liebl M, Daehnert E, Zimmermann M, Knappe-Drzikova B, Rolker S, Nunier B, Algharably E, Pirmorady Sehouli A, Zwantleitner L, Krull A, Heitz F, Ataseven B, Chekerov R, Harter P, Schneider S. Inci MG, et al. Among authors: chekerov r. Int J Gynecol Cancer. 2023 Aug 7;33(8):1304-1309. doi: 10.1136/ijgc-2023-004531. Int J Gynecol Cancer. 2023. PMID: 37208019 Clinical Trial.
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
Chekerov R, Arndt T, Pietzner K, Canzler U, Wimberger P, Strauß HG, Mahner S, Woelber L, de Gregorio N, Stocker G, von Abel E, Neunhoeffer T, Belau AK, Mustea A, Yalinkaya I, Braicu EI, Richter R, Sehouli J; NOGGO ovarian cancer study group. Chekerov R, et al. J Cancer Res Clin Oncol. 2023 Aug;149(10):7637-7649. doi: 10.1007/s00432-023-04647-9. Epub 2023 Mar 31. J Cancer Res Clin Oncol. 2023. PMID: 37000264 Free PMC article. Clinical Trial.
Participation of elderly gynecological cancer patients in clinical trials.
Prieske K, Trillsch F, Oskay-Özcelik G, Chekerov R, Bleich C, Oliveira-Ferrer L, Grimm D, Kuerti S, Mueller V, Suling A, Schmalfeldt B, Sehouli J, Mahner S, Woelber L. Prieske K, et al. Among authors: chekerov r. Arch Gynecol Obstet. 2018 Oct;298(4):797-804. doi: 10.1007/s00404-018-4886-2. Epub 2018 Aug 30. Arch Gynecol Obstet. 2018. PMID: 30167853
Ten years of live surgical broadcast at Charité-MAYO conferences (2010-2019): a systematic evaluation of the surgical outcome.
Altmann J, Chekerov R, Fotopoulou C, Muallem MZ, du Bois A, Cliby W, Dowdy S, Podratz K, Lichtenegger W, Camara O, Tunn R, Cibula D, Kuemmel S, Scambia G, Vergote I, Chiantera V, Pietzner K, Inci MG, Chopra S, Biebl M, Neymeyer J, Blohmer JU, Sehouli J. Altmann J, et al. Among authors: chekerov r. Int J Gynecol Cancer. 2022 Jun 6;32(6):746-752. doi: 10.1136/ijgc-2021-003173. Int J Gynecol Cancer. 2022. PMID: 35383091
Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment.
Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel T, Taube E, Darb-Esfahani S, Mangler M, Sehouli J, Chekerov R, Braicu EI, Meyer TF, Kessler M. Hoffmann K, et al. Among authors: chekerov r. EMBO J. 2020 Mar 16;39(6):e104013. doi: 10.15252/embj.2019104013. Epub 2020 Feb 3. EMBO J. 2020. PMID: 32009247 Free PMC article.
Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Lee BN, Jung S, Darvin ME, Eucker J, Kühnhardt D, Sehouli J, Chekerov R, Patzelt A, Fuss H, Yu RX, Lademann J. Lee BN, et al. Among authors: chekerov r. Anticancer Res. 2016 Aug;36(8):4089-93. Anticancer Res. 2016. PMID: 27466518
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke C, Kulbe H, Dreher F, Taube ET, Chekerov R, Horst D, Hummel M, Kessler T, Pietzner K, Kassuhn W, Heitz F, Muallem MZ, Lang SM, Vergote I, Dorigo O, Lammert H, du Bois A, Angelotti T, Fotopoulou C, Sehouli J, Braicu EI. Keunecke C, et al. Among authors: chekerov r. Gynecol Oncol. 2022 Aug;166(2):334-343. doi: 10.1016/j.ygyno.2022.06.010. Epub 2022 Jun 21. Gynecol Oncol. 2022. PMID: 35738917
79 results